Themis Medicare Ltd

Themis Medicare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 20 September 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

Themis Medicare Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a marked improvement in technical indicators, even as its fundamental financial performance remains under pressure. This nuanced change reflects a complex interplay of quality, valuation, financial trend, and technical factors that investors should carefully consider.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, signalling a transition from a mildly bullish to a more confident bullish trend. This change is underscored by a strong 10.41% surge in the stock price on 8 Sep 2026, reflecting renewed investor interest and positive technical indicators across multiple timeframes.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 1 September 2026. This shift reflects a complex interplay of deteriorating financial fundamentals, challenging valuation metrics, and nuanced technical indicators, despite the company’s recent market-beating stock performance.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish indicators. Despite a recent downgrade in its Mojo Grade to a Strong Sell, the stock’s price action and technical parameters reveal a cautiously optimistic outlook amid mixed signals from key momentum indicators.

Themis Medicare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 August 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 August 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 14 Aug 2026. This revision reflects significant deterioration across key parameters including financial performance, quality metrics, and technical indicators, signalling heightened risk for investors despite a modest day gain of 0.67% on 17 Aug 2026.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its quality grade downgraded from average to below average, reflecting deteriorating business fundamentals. Despite a modest share price increase of 0.67% on 17 Aug 2026, the company faces significant headwinds in profitability, debt management, and operational efficiency, raising concerns for investors amid a challenging industry backdrop.

Themis Medicare Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 August 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant deterioration in its financial performance for the quarter ended June 2026. Despite recording its highest quarterly earnings per share (EPS) at Rs 2.67, the company’s profitability metrics and operational efficiency have sharply declined, prompting a downgrade in its Mojo Grade from Hold to Sell as of 30 June 2026.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent decline in price, the stock’s technical indicators present a nuanced picture, reflecting both positive and cautious signals for investors navigating this evolving landscape.

Themis Medicare Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is underscored by positive signals from key technical indicators such as MACD, moving averages, and KST, despite mixed readings from RSI and Bollinger Bands. The stock’s recent price action and technical upgrades offer investors a nuanced perspective on its near-term potential within the Pharmaceuticals & Biotechnology sector.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent day decline of 1.95%, the stock’s technical indicators reveal a complex interplay of signals that suggest cautious optimism for investors navigating this evolving landscape.

Themis Medicare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, upgrading its MarketsMOJO grade from Sell to Hold as of 30 June 2026. This change reflects improving price action and technical indicators that suggest a more bullish outlook for the stock, despite mixed signals from some monthly metrics.

Themis Medicare Ltd is currently rated 'Hold' by MarketsMOJO, with this rating last updated on 30 June 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's present position as of 03 August 2026, providing investors with the most up-to-date view of the company’s fundamentals and market performance.